Kaya, the London and Paris-based CBD and adaptogenic brand, has raised £1.7million in funding from new and existing investors including Senseii Ventures (VC fund) and Artemis Growth (US Cannabis Fund).
Launched in November 2019, Kaya uses natural adaptogenic plants along with CBD in its products, which help to alleviate stress.
Kaya stated that the funding will help it as it expands into wider European markets, most recently in Italy, Germany and Poland.
The company reported that it has served 15,000 customers since last September and expects its 2021 revenue to be £5-8 million, adding that it has achieved major retailer distribution across the UK.
Ludovic Rachou, co-founder of Kaya, said: “At Kaya, we’re committed to delivering quality products with the potential to have a real impact on consumers day to day and this latest wave of funding puts us one step closer to achieving this goal. The CBD category has been growing hugely over previous years, and we aspire to be the go-to CBD brand for consumers across the UK and beyond – providing a truly great product that shoppers can trust. Kaya was born from the needs of myself and my co-founders, who are all living busy, stressful lives like millions of others, and we hope that Kaya can be an ally to many more.”
In March, Kaya had its application for novel foods certification for its CBD-based products verified by the Food Standards Agency and European Food Standards Agency.
The Kaya range is vegan-friendly and includes 10 adaptogenic and CBD-based products offering a variety of benefits, from restful sleep to everyday stress relief. The products are available online and in health shops such as Flawless, Mellow and Alphagreen.
Date published: 11 August 2021